MLNT
Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries
- Total consideration of up to $265 million (including potential royalties) -
- Expands on existing commercial and co-development agreement for Baxdela® (delafloxacin)
CELG, REGN, TSRO, PBYI
Upgrades de Cantor de las que llevamos por aquí
Celgene (NASDAQ: CELG) initiated with Overweight rating and $100 (16% upside) price target at Cantor. Shares up 1% premarket.
Puma Biotechnology (NYSE: PBYI) initiated with Overweight rating and $75 (63% upside) price target at Cantor.
Regeneron Pharmaceuticals (NASDAQ: REGN) initiated with Neutral rating and $415 (3% upside) price target at Cantor. Shares up 2% premarket.
TESARO (NASDAQ: TSRO) initiated with Overweight rating and $57 (46% upside) price target at Cantor. Shares up 1% premarket.
MLNT
68 countries,ohoooo y eso que falta Baxdela que de momento solo esta aprobada para Inf Cutaneas, cuando la aprueben para pneumonias , venders mas ,.... parece que en un par de año va a ser un empreson,
,ja,ja,ja,
MLNT
Dentro a 4.30
TGTX
Dentro a 5.50
News is posted throughout the day, so visit
thepharmaletter.com for the latest updates.
Look back at pharma news in week to September 28
Last week’s top news stories including some positive and exciting new research data, including Amarin's…
Read more »
FDA approves Sanofi and Regeneron’s Libtayo
USA-based Regeneron Pharmaceuticals and French pharma major Sanofi scored a hit on Friday, when the US…
Read more »
Insmed's lung disease drug Arikayce approved in USA
The US Food and Drug Administration late Friday granted accelerated approval of Arikayce (amikacin liposome…
Read more »
China taking actions for the fast approval of new drugs
In an expert view, Maggie Chang, vice president, regulatory affairs, at China-based Hangzhou Tigermed…
Read more »
Geron and Janssen part ways over imetelstat
US biotech Geron has been handed back rights to its elomerase inhibitor, imetelstat, from erstwhile partner…
Read more »
Actinium: Improving access to CAR-T therapy
With its molecular-targeted radio-therapy Iomab-B showing promise and in a pivotal Phase III for bone…
Read more »
AAM urges action on biosimilars
The US trade group for generics and biosimilars companies has underlined the steps that the US Food and…
Read more »
Bayer appeals against ‘unlawful’ bevacizumab ruling
A week after a UK court judged that bevacizumab injections could be prescribed for the treatment of wet…
Read more »
BRIEF — Takeda and Lundbeck seek Japanese approval with depression drug
A New Drug Application has been submitted to the Japanese Ministry of Health, Labour and Welfare for…
Read more »
FDA approves Pfizer’s Vizimpro as first-line rare NSCLC treatment
Though a long time coming given earlier failure in two clinical trials in 2014, the US Food and Drug…
Read more »
FDA nod for another EpiPen alternative
Sandoz is to sell a new alternative to Mylan’s EpiPen (epinephrine) in the USA for the emergency treatment…
Read more »
Lilly's Emgality enters migraine market with free offer
Eli Lilly has just received US Food and Drug Administration (FDA) approval with its entry into the emerging…
Read more »
Drug enforcement agency gives green light to Epidiolex
The US Drug Enforcement Administration (DEA) has given the nod for GW Pharmaceuticals to retail its cannabis-based…
Read more »
Roche makes bolt-on I-O acquisition
Swiss pharma giant Roche has made a third bolt-on acquisition this year, today taking control of Tusk…
Read more »
RNAi approach gathers steam with more positive data for Alnylam
East Coast, USA-based Alnylam Pharmaceuticals has released positive topline results from an interim analysis…
Read more »
BRIEF—Takeda shareholders to vote on Shire deal
Takeda Pharmaceutical has announced it will hold a general meeting of shareholders on October 19, to…
Read more »
Bayer Pharma replaces head of Americas with Sebastian Guth
German pharma major Bayer has appointed Sebastian Guth as president of Pharmaceuticals, Americas Region,…
Read more »
UK biotech fundraising in 2018 at £1.5 billion so far, exceeds previous year
UK biotechnology companies have already raised more than £1.5 billion ($1.97 billion) in 2018, surpassing…
Read more »
SYNERGY PHARMACEUTICALS TO PRESENT NEW ANALYSES OF TRULANCE® (PLECANATIDE) AT THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG) ANNUAL SCIENTIFIC MEETING
OCTOBER 01, 2018
New analyses further reinforce effectiveness and safety in important subpopulations of adults with CIC or IBS-C
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that two posters will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, October 5-10, 2018, in Philadelphia, PA.
Presentations include a poster detailing outcomes from a large post-hoc analysis evaluating the safety and tolerability of TRULANCE® (plecanatide) in chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in patients aged 65 and older compared to those in a younger cohort (≥18 to <65).
Synergy will also present data from a post-hoc analysis which evaluated the efficacy and safety of TRULANCE therapy when given in combination with acid suppression medications.
The findings will be presented via poster presentations as follows:
Evaluation of the Safety and Tolerability of Plecanatide in CIC and IBS-C Patients Aged 65 and Older (P0335), to be presentedon Sunday, October 7, 2018 from 5:15 p.m. – 6:30 p.m. ET, by Stacy B. Menees, M.D., M.S., University of Michigan, Ann Arbor, MI
Acid Suppression Therapy Does Not Affect the Efficacy of Plecanatide: A Patient-Level Pooled Analysis of Two Large Randomized Controlled Trials (P1222), to be presented on Monday, October 8, 2018, 1:00 p.m. – 2:15 p.m. ET, by Baharak Moshiree, M.D., FACG, Professor of Medicine, University of North Carolina, Atrium Health, Charlotte, NC
ADXS
Se ve que ha debido ser un éxito la presentación de la conferencia que tenían hoy...
SGYP
He telefonado a la Head Office y me han dicho -- Soltamos ese PR para que ese de uds ahi ...
NO SE ABURRA , huuuuuuffff
